Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Atopic dermatitis entities : Abbvie inc. save search
U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis
Published: 2022-01-14 (Crawled : 19:00) - prnewswire.com
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
| Email alert
Add to watchlist
rinvoq fda atopic dermatitis dermatitis children order
AbbVie Presents New Analyses Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual Congress
Published: 2021-09-30 (Crawled : 19:00) - biospace.com/
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.33%
H: 1.12%
C: -1.22%
dermatitis atopic dermatitis
European Commission Approves RINVOQ® (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Published: 2021-08-24 (Crawled : 14:00) - biospace.com/
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: -0.03%
treatment europe dermatitis atopic dermatitis
Global Atopic Dermatitis Drugs Market Report 2021: Rising Incident of Food Allergies Intensifying Atopic Dermatitis - Forecast to 2026
Published: 2021-08-19 (Crawled : 23:00) - prnewswire.com
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.56%
H: 0.87%
C: 0.7%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.17%
H: 0.67%
C: 0.26%
LLY | News | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
BHC | $8.6 -0.69% 0.0% 2.1M
|
Health Technology
|
| O: 0.04%
H: 1.71%
C: 0.18%
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.14%
H: 1.16%
C: 0.61%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
food dermatitis drug atopic dermatitis
JAMA Dermatology Publishes Data Showing RINVOQ® (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) for Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis
Published: 2021-08-04 (Crawled : 19:00) - biospace.com/
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.4%
H: 0.64%
C: -0.6%
dermatitis phase 3 atopic dermatitis dupixent
AbbVie Provides Update Regarding RINVOQ® (upadacitinib) for the Treatment of Moderate to Severe Atopic Dermatitis in the U.S.
Published: 2021-07-16 (Crawled : 14:00) - biospace.com/
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.62%
H: 0.36%
C: -0.35%
treatment dermatitis atopic dermatitis
CHMP Recommends Approval of RINVOQ® (upadacitinib) for the Treatment of Atopic Dermatitis
Published: 2021-06-25 (Crawled : 07:00) - prnewswire.com
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -1.6%
H: 0.61%
C: 0.07%
treatment dermatitis approval chmp atopic dermatitis
The Lancet Publishes Results from Pivotal Global Phase 3 Program Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis
Published: 2021-05-24 (Crawled : 13:00) - prnewswire.com
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.4%
H: 0.19%
C: -0.58%
results dermatitis phase 3 atopic dermatitis lancet
AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Moderate to Severe Atopic Dermatitis
Published: 2021-04-02 (Crawled : 22:00) - prnewswire.com
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
| Email alert
Add to watchlist
new drug treatment dermatitis drug atopic dermatitis
RINVOQ™ (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis
Published: 2020-12-10 (Crawled : 14:12) - prnewswire.com
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.36%
H: 0.01%
C: -1.44%
dermatitis phase 3 atopic dermatitis dupixent
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.